Breakthrough in Breast Cancer Treatment: Nanotechnology-Based Therapy

Strategic Insights -

Researchers at Government College University in Lahore, Pakistan, have made a significant breakthrough in the treatment of breast cancer by combining a naturally occurring silkworm protein (sericin) with nanoparticle formulations. This novel approach has shown promise in overcoming drug resistance and providing a safer and more effective delivery method for cancer treatment. The study, published in the journal Microscopy Research and Technique, demonstrated that sericin-conjugated nanoparticles induced more efficient anti-breast tumor effects in animal models.

Key Takeaways:

  • The study involved combining sericin with nanoparticle formulations to explore the anticancer effects in breast cancer.
  • The research used a breast cancer animal model developed by using 7, 12-dimethylbenz(a)anthracene (DMBA), a carcinogenic compound.
  • The mice were treated with two different concentrations of individual sericin protein, along with conjugated silver nanoparticles (100-200 mg/kg, b.w.).
  • The biochemical results showed that sericin and its conjugated nanoparticles had significant effects against the DMBA-induced carcinogenic group in comparison with the untreated control group.
  • The histopathological analysis of the spleen and mammary tissues showed cytotoxic effects in the DMBA group, and sericin-conjugated NPs were highly effective in minimizing these effects.
  • The study concluded that sericin-conjugated nanoparticles have promising future clinical applications in overcoming drug resistance.
  • The research has been peer-reviewed and published in the journal Microscopy Research and Technique.

Statistics:

  • 7, 12-dimethylbenz(a)anthracene (DMBA) was used to develop the breast cancer animal model.
  • The mice were treated with two different concentrations of individual sericin protein, along with conjugated silver nanoparticles (100-200 mg/kg, b.w.).
  • The dose of sericin protein used was 100-200 mg/kg body weight.
  • The study was conducted over a period of 60 days.

Sources:

  • Biochemical and Histopathological Impact of DMBA-Induced Breast Cancer and Therapeutic Potential of Silk Sericin and Sericin Silver Nanoparticles. Microscopy Research and Technique, 2025.
  • Wiley, 111 River St, Hoboken 07030-5774, NJ, USA (Publisher contact information for Microscopy Research and Technique).
  • Government College University, Lahore, Pakistan (Research institution mentioned in the study).
  • NewsRx. Government College University Reports Findings in Breast Cancer (Biochemical and Histopathological Impact of DMBA-Induced Breast Cancer and Therapeutic Potential of Silk Sericin and Sericin Silver Nanoparticles). Nanotechnology Weekly. June 16, 2025; p 1314.